Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Albanell Mestres, Joanca
- dc.contributor.author iMolins, A. B.ca
- dc.contributor.author Martínez, L. C.ca
- dc.contributor.author López-Muñiiz, J. I. C.ca
- dc.contributor.author Gil, E. C.ca
- dc.contributor.author Juan Ferré, A. deca
- dc.contributor.author Barco Berrón, Sonia delca
- dc.contributor.author Pérez, Y. F.ca
- dc.contributor.author Mata, J. G.ca
- dc.contributor.author Palomo, A. G.ca
- dc.contributor.author Gregori, J. G.ca
- dc.contributor.author Pardo, P. G.ca
- dc.contributor.author Mañas, J. J. I.ca
- dc.contributor.author Hernández, A. L.ca
- dc.contributor.author Dueñas-Espín, Iván, 1979-ca
- dc.contributor.author Jáñez, N. M.ca
- dc.contributor.author Murillo, S. M.ca
- dc.contributor.author Bofill, Javier Salvadorca
- dc.contributor.author Auñón, Pilar Zamoraca
- dc.contributor.author Sánchez-Rovira, Pedroca
- dc.date.accessioned 2017-01-31T12:39:07Z
- dc.date.issued 2017
- dc.description.abstract Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting a systemic treatment, it is important to consider the medication administered in the previous stages, such as acquired resistance, type of progression, time to relapse, tumor aggressiveness, age, comorbidities, pre- and post-menopausal status, and patient preferences. Moreover, tumor genomic signatures can identify different subtypes, which can be used to create patient profiles and design specific therapies. However, there is no consensus regarding the best treatment sequence for each subgroup of patients. During the SABCC Congress of 2014, specialized breast cancer oncologists from referral hospitals in Europe met to define patient profiles and to determine specific treatment sequences for each one. Conclusions were then debated in a final meeting in which a relative degree of consensus for each treatment sequence was established. Four patient profiles were defined according to established breast cancer phenotypes: pre-menopausal patients with luminal subtype, post-menopausal patients with luminal subtype, patients with triple-negative subtype, and patients with HER2-positive subtype. A treatment sequence was then defined, consisting of hormonal therapy with tamoxifen, aromatase inhibitors, fulvestrant, and mTOR inhibitors for pre- and post-menopausal patien ts; a chemotherapy sequence for the first, second, and further lines for luminal and triple-negative patients; and an optimal sequence for treatment with new antiHER2 therapies. Finally, a document detailing all treatment sequences, that had the agreement of all the oncologists, was drawn up as a guideline and advocacy tool for professionals treating patients with this disease.ca
- dc.format.mimetype application/pdfca
- dc.identifier.citation Albanell Mestres J, iMolins AB, Martínez LC, López-Muñiz JI, Gil EC, Juan Ferré A de. et al. Defining the optimal sequence for the systemic treatment of metastatic breast cancer. Clin Transl Oncol. 2017 Feb;19(2):149-161. doi: 10.1007/s12094-016-1520-2ca
- dc.identifier.doi http://dx.doi.org/10.1007/s12094-016-1520-2
- dc.identifier.issn 1699-048X
- dc.identifier.uri http://hdl.handle.net/10230/28015
- dc.language.iso engca
- dc.publisher Springerca
- dc.relation.ispartof Clinical and Translational Oncology. 2017 Feb;19(2):149-61
- dc.rights This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.ca
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri https://creativecommons.org/licenses/by/4.0/
- dc.subject.other Mama -- Càncer -- Quimioteràpiaca
- dc.subject.other Quimioteràpiaca
- dc.subject.other Metàstasica
- dc.title Defining the optimal sequence for the systemic treatment of metastatic breast cancer.ca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/publishedVersionca